Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Nature

• Publication date

  1983-11-17

• Fields of study

  Biology, Medicine, Geology

• Identifiers
  DOI 10.1038/306277A0PMID 6580527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of a complex philadelphia translocation (1p-;9q+;22q-) by gene mapping

  2004cited by this paper
• Transcriptional activation of the translocated c-myc oncogene in burkitt lymphoma.

  1983cited by this paper
• Lambda Ig constant region genes are translocated to chromosome 8 in Burkitt's lymphoma with t(8;22).

  1983cited by this paper
• Identification of the constant chromosome regions involved in human hematologic malignant disease.

  1982cited by this paper
• A photometric study of the standard Philadelphia (Ph1) translocation of chronic myeloid leukemia (CML).

  1982cited by this paper
• Chromosomal location of human kappa and lambda immunoglobulin light chain constant region genes

  1982cited by this paper
• Chromosomal localization of human cellular homologues of two viral oncogenes

  1982cited by this paper
• A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

  1982cited by this paper
• Assignment of the genes for human λ immunoglobulin chains to chromosome 22

  1981cited by this paper
• The role of gene dosage and genetic transpositions in carcinogenesis

  1981cited by this paper
• Assignment of the genes for human lambda immunoglobulin chains to chromosome 22.

  1981cited by this paper
• The cytogenetics of chronic myelocytic leukemia (CML): Chronic phase and blastic crisis

  1980cited by this paper
• Physical mapping of the globin gene deletion in hereditary persistence of foetal haemoglobin (HPFH).

  1980cited by this paper
• Nucleoside conformation is determined by the electronegativity of the sugar substituent.

  1980cited by this paper
• Ph1-positive leukaemia, including chronic myelogenous leukaemia.

  1980cited by this paper
• Evolution of karyotypes in philadelphia (Ph1) chromosome‐negative chronic myelogenous leukemia

  1979cited by this paper
• Chromosomal location of the genes for human immunoglobulin heavy chains.

  1979cited by this paper
• Quantification by DNA-based cytophotometry of the 9q+/22q-chromosomal translocation associated with chronic myelogenous leukemia.

  1977cited by this paper
• A physical map of the DNA regions flanking the rabbit beta-globin gene.

  1977cited by this paper
• A physical map of the DNA regions flanking the rabbit β-globin gene

  1977cited by this paper
• DNA Content and DNA-Based Centromeric Index of the 24 Human Chromosomes

  1973cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• Philadelphia-chromosome-positive and -negative chronic myelocytic leukemia.

  1970cited by this paper

• Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms

  2025cites this paper
• A retrospective evaluation of chronic myeloid leukemia patients treated with imatinib

  2025cites this paper
• Trans-localization of p210 BCR-ABL to the mitochondria is mediated by the interaction of its PH domain with cardiolipin exposed on the outer membrane.

  2025cites this paper
• A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over time

  2025influential citation
• Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities

  2025cites this paper
• Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature

  2025cites this paper
• 5-FU@HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia

  2025cites this paper
• Analysis of lipids by Raman spectroscopy and mass spectrometry provides a detection tool and mechanistic insight into imatinib resistance in CML-BC.

  2025cites this paper
• mTOR inhibition by AZD2014 alleviates BCR::ABL1 independent imatinib resistance through enhancing autophagy in CML resistant cells.

  2024cites this paper
• The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia

  2024cites this paper
• Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients

  2024cites this paper
• 3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression

  2024cites this paper
• Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes

  2024cites this paper
• 3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression

  2024cites this paper
• Cytogenetics and genomics in CML and other myeloproliferative neoplasms.

  2024cites this paper
• Tyrosine Kinase Inhibitors in Cancers: treatment optimization - Part I.

  2024cites this paper
• REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity

  2024cites this paper
• Caspase-Activated DNase localizes to cancer causing translocation breakpoints during cell differentiation

  2024cites this paper
• A fluorescence‐based sensor for calibrated measurement of protein kinase stability in live cells

  2024cites this paper
• The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia

  2024cites this paper
• BCAT1 contributes to the development of TKI-resistant CML

  2024cites this paper
• PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives

  2024cites this paper
• The rapidly changing field of predictive biomarkers of non-small cell lung cancer

  2024cites this paper
• Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors

  2023cites this paper
• Genome-guided discovery of cancer therapeutic targets.

  2023cites this paper
• Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review

  2023cites this paper
• Brassinin Induces Apoptosis, Autophagy, and Paraptosis via MAPK Signaling Pathway Activation in Chronic Myelogenous Leukemia Cells

  2023cites this paper
• A Fluorescence-Based Sensor for Calibrated Measurement of Protein Kinase Stability in Live Cells

  2023cites this paper
• Case report: Deep molecular remissions post two separate CD19-targeted chimeric antigen receptor T-cell therapies do not prevent disease from relapsing in Philadelphia chromosome-positive acute lymphoblastic leukemia

  2023cites this paper
• Development of covalent inhibitors: Principle, design, and application in cancer

  2023cites this paper
• Identification of rare atypical BCR-ABL1 transcript: A case report

  2023cites this paper
• Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights

  2023cites this paper
• Quantitative Cell Proteomic Atlas: Pathway-scale targeted mass spectrometry for high-resolution functional profiling of cell signaling

  2022cites this paper
• Mechanism of treatment-free remission in patients with chronic myeloid leukemia revealed by a computational model of CML evolution

  2022cites this paper
• 2-Methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223/Fms-like tyrosine kinase 3/phosphatidylinositol-3 kinase/protein kinase B axis

  2022cites this paper
• Chronic myeloid leukemia: a type of MPN

  2022cites this paper
• Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy

  2022influential citation
• The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways

  2022cites this paper
• Targeting MDC1 promotes apoptosis and sensitizes Imatinib resistance in CML cells by mainly disrupting non-homologous end-joining repair

  2022cites this paper
• Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance

  2022cites this paper
• The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia

  2022cites this paper
• It is time for a moonshot to find "Cures" for diabetic retinal disease.

  2022cites this paper
• Precision medicine in myeloid malignancies.

  2021cites this paper
• IRF4 deficiency vulnerates B progeny for leukemogenesis via Jak3 mutations resembling Ph-like B-ALL in humans

  2021cites this paper
• An updated account on molecular heterogeneity of acute leukemia.

  2021cites this paper
• Molecular Biology for BCR-ABL1 Quantification for Chronic Myeloid Leukemia Monitorization and Evaluation

  2021cites this paper
• Chronic myeloid leukaemia.

  2021cites this paper
• Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia

  2021cites this paper
• Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer

  2021cites this paper
• Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3–amplified lung adenocarcinoma cells

  2021cites this paper
• The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML

  2021cites this paper
• Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia

  2021cites this paper
• Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

  2021cites this paper
• Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

  2021cites this paper
• Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics

  2021cites this paper
• US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy

  2021cites this paper
• Cytogenetics of Chronic Myeloid Leukemia (CML)

  2021cites this paper
• Tyrosine Kinases in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis and Potential Therapeutic Role of their Inhibition.

  2021cites this paper
• Chapter 17: Oncology: Somatic Disease and Pharmacogenomics

  2020cites this paper
• The landscape of BCR‐ABL mutations in patients with Philadelphia chromosome‐positive leukaemias in the era of second‐generation tyrosine kinase inhibitors

  2020cites this paper
• Hematopathology

  2020cites this paper
• Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells

  2020cites this paper
• Rational Design of Potential Bcr-Abl Tyrosine Kinase Inhibitors by the Methods of Molecular Modeling

  2020cites this paper
• P210 breakpoint is associated with less minimal residual disease compared to p190 breakpoint in acute lymphoblastic leukemia patients with Philadelphia chromosome

  2020cites this paper
• The chronic myeloid leukaemia story in the United Kingdom since 1960

  2020cites this paper
• NHD2-15, a novel antagonist of Growth Factor Receptor-Bound Protein-2 (GRB2), inhibits leukemic proliferation

  2020cites this paper
• Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells

  2020cites this paper
• Leucémie myéloïde chronique

  2020cites this paper
• Molecular diagnostics in hematopathology

  2020cites this paper
• Selective and sensitive detection of chronic myeloid leukemia using fluorogenic DNAzyme probes.

  2020cites this paper
• Leucémies chroniques

  2020cites this paper
• CRISPR/Cas9-mediated microRNA-21 Cleavage Sensitizes the Treatment 1 Response to Dasatinib in Chronic Myeloid Leukemia Cell Line K562

  2020cites this paper
• A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway

  2020cites this paper
• Molecular/Cytogenetic Education for Hematopathology Fellows.

  2020cites this paper
• Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse

  2020cites this paper
• Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process

  2019cites this paper
• Human Genomic Variants and Inherited Disease

  2019cites this paper
• GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia

  2019cites this paper
• Molecular Diagnostics in Cancer: A Fundamental Component of Precision Oncology

  2019cites this paper
• Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia

  2019cites this paper
• NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

  2019cites this paper
• Chronic Myeloid Neoplasms

  2019cites this paper
• Advances in measurable residual disease monitoring for adult acute lymphoblastic leukemia

  2019cites this paper
• Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib-based therapy

  2019cites this paper
• Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib

  2019cites this paper
• Imatinib Induced Delayed and Refractory Generalized Fluid Retention: A Case Report and Review of Literature

  2019cites this paper
• 酪氨酸激酶抑制剂治疗慢性髓性白血病继发Ph阴性+8染色体异常骨髓增生异常综合征一例报告并文献复习

  2019cites this paper
• Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review

  2019cites this paper
• Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

  2018cites this paper
• Kinase-targeted cancer therapies: progress, challenges and future directions

  2018cites this paper
• Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.

  2018cites this paper
• Nuclear-Cytoplasmic Transport

  2018cites this paper
• A large-scale RNA interference screen identifies genes that regulate autophagy at different stages

  2018cites this paper
• Myeloid Leukemia Vaccines

  2018cites this paper
• Xiao-AiPing inhibits proliferation and induces apoptosis of chronic myeloid leukemia cells through downregulating β-catenin signaling pathway

  2018cites this paper
• Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

  2018cites this paper
• How I investigate Eosinophilia

  2018cites this paper
• Genetic Models of Leukemia in Zebrafish

  2018cites this paper
• Traitement de maintenance par des doses alternées de dasatinib dans la leucémie myéloïde chronique

  2018cites this paper
• Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States

  2018cites this paper